September 19, 2019
Context Therapeutics and Jefferson Health to evaluate Apristor combination therapy for women with advanced endometrial cancer
Apristor, an oral progesterone receptor antagonist, is being studied in combination with an antiestrogen in advanced ER+,PR+,HER2- endometrial cancer Study…